Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717-726.
Bubser M, Bridges TM, Dencker D, et al. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci. 2014;5:920-942.
Caplyta™ (lumateperone) [prescribing information]. Intra-Cellular Therapies, Inc. Approved 2019. Revised December 2019.
Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharm Des. 2013;19:1311-1320.
ClinicalTrials.gov. A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. NCT04109950. Updated November 13, 2020. Accessed June 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04109950
ClinicalTrials.gov. A clinical trial that will study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. NCT04092686. Updated October 14, 2020. Accessed June 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04092686
ClinicalTrials.gov. A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. NCT04072354. Updated April 14, 2021. Accessed June 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04072354
ClinicalTrials.gov. A phase 2 study to evaluate the safety and efficacy of CTP-692 as an adjunctive treatment in adults with schizophrenia. NCT04158687. Updated February 4, 2021. Accessed June 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04158687
ClinicalTrials.gov. A study of the long-term safety and tolerability of an investigational drug in people with schizophrenia. NCT04115319. Updated November 13, 2020. Accessed May 5, 2021. https://clinicaltrials.gov/ct2/show/NCT04115319
ClinicalTrials.gov. Efficacy and safety of pimavanserin as adjunctive treatment for the negative symptoms of schizophrenia (ADVANCE). NCT02970305. Updated December 22, 2020. Accessed June 8, 2021. https://clinicaltrials.gov/ct2/show/results/NCT02970305
ClinicalTrials.gov. Study with Lu AF11167 for the treatment of negative symptoms in patients with schizophrenia. NCT03793712. Updated November 13, 2020. Accessed September 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03793712
Davidson M, Saoud J, Staner C, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017;174:1195-1202.
Dean B, Scarr E. Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia. Psychiatry Res. 2020;288:112989.
Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371:1-14.
Eiden LE, Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci. 2011;1216:86-98.
Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201.
Gray L, van den Buuse M, Scarr E, et al. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol. 2009;12:45-60.
Harvey PD, Saoud JB, Luthringer R, et al. Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: reduced emotional experience and reduced emotional expression. Schizophr Res. 2020;215:352-356.
Jones CK, Byun N, Bubster M, et al. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012;37:16-42.
Kanahara N, Yamanaka H, Suzuki T, et al. First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort. BMC Psychiatry. 2018;18:274.
Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121:125-130.
Koblan K, Hopkins S, Justine K, et al. Efficacy and safety of SEP-363856, a novel psychotropic agent with a non-D2 mechanism of action, in the treatment of schizophrenia: a 4-week, randomized, placebo-controlled trial. Schizophrenia Bulletin. 2019;45(suppl_2): Abstract O12.5.
Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382:1497-1506.
Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24:38-69.
Kruse AC, Kobilka BK, Gautam D, et al. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov. 2014;13:549-560.
Macek TA, McCue M, Dong X, et al. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2019;204:289-294.
Matsumoto I, Inoue Y, Iwazaki T, et al. 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett. 2005;379:164-168.
Miller GM. The emerging role of trace amine associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. 2011;116:164-176.
Plitman E, Nakajima S, de la Fuente-Sandoval C, et al. Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol. 2014;24:1591-1605.
Scarr E, Cowie TF, Kanellakis S, et al. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry. 2009;14:1017-1023.
Schwartz MD, Canales JJ, Zucchi R, et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets. 2018;22:513-526.
Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033-1039.
Stahl SM. Antipsychotic agents. Stahl’s Essential Psychopharmacology. 4^th ed. Cambridge University Press; 2013.
Stahl SM. Antipsychotic agents. In: Stahl's Essential Psychopharmacology. 4th ed. Cambridge University Press;2013:131-235.
Stahl SM. Psychosis and schizophrenia. In: Stahl's Essential Psychopharmacology. 4th ed. Cambridge University Press;2013:79-128.
Sullivan RJ, Andres S, Otto C, et al. The effects of an indigenous muscarinic drug, betel nut (Areca catechu), on the symptoms of schizophrenia: a longitudinal study in Palau, Micronesia. Am J Psychiatry. 2007;164:670-673.
Suzuki K, Kimura H. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. CNS Neurosci Ther. 2018;24:604-614.
Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73:204-215.
Wimalasena K. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011;31:483-519.
Yoneyama T, Sato S, Sykes A, et al. Mechanistic multilayer quantitative model for nonlinear pharmacokinetics, target occupancy, and pharmacodynamics (PK/TO/PD) relationship of D-amino acid oxidase inhibitor, TAK-831 in mice. Pharm Res. 2020;37:164.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Christoph Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine
Hofstra/Northwell
Glen Oaks, New York
Professor of Child and Adolescent Psychiatry
Charité University of Medicine
Berlin, Germany

Disclosures

Disclosure: Christoph Correll, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acadia; Alkermes; Allergan; Angelini; Gedeon Richter; IntraCellular Therapies; Janssen/J&J; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Merck; Mitsubishi Tanabe Pharma; Mylan; Neurocrine; Noven; Otsuka; Pfizer; Recordati; Rovi; Sumitomo Dainippon; Sunovion; Supernus; Takeda; Teva
Served as a speaker or a member of a speakers bureau for: Angelini; Gedeon Richter; Janssen/J&J; Lundbeck; Mitsubishi Tanabe Pharma; Mylan; Sumitomo Dainippon; Otsuka; Recordati; Sunovion
Received grants for clinical research from: Janssen; Takeda
Owns stock, stock options, or bonds from: LB Pharma
Other: DSMB member or chair: Lundbeck; Relmada; ROVI; Teva

Diana Perkins, MD

Professor
Department of Psychiatry
Director of Early Psychosis Interventions-North Carolina Consultants
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Disclosures

Disclosure: Diana Perkins, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alkermes
Received grants for clinical research from: Boehringer Ingelheim

Editors

Lisette Arnaud-Hevi, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisette Arnaud-Hevi, PhD, has disclosed no relevant financial relationships.

Walid Amara, MD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Biotronix; Servier. Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; LivaNova; MEDA; Medtronic, Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Physiomed; St. Jude, Servier

Christin Melton, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Christin Melton, ELS, has disclosed no relevant financial relationships.

CME Reviewer

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

The Emerging Receptor Science in the Management of Schizophrenia

Authors: Christoph Correll, MD; Diana Perkins, MD
CME Released: 6/10/2021; Reviewed and Renewed: 9/14/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/14/2023, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for psychiatrists and primary care physicians.

The goal of this activity is to increase knowledge of how new scientific findings related to the pathophysiology of schizophrenia are resulting in new therapies for schizophrenia.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Roles of different receptor types in schizophrenia
- Potential utility of trace amine-associated receptor 1 (TAAR1) activation in the management of schizophrenia
Have greater competence related to
- Recognizing the limitations of current treatments

Disclosures

Faculty

Christoph Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine
Hofstra/Northwell
Glen Oaks, New York
Professor of Child and Adolescent Psychiatry
Charité University of Medicine
Berlin, Germany

Disclosures

Disclosure: Christoph Correll, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Acadia; Alkermes; Allergan; Angelini; Gedeon Richter; IntraCellular Therapies; Janssen/J&J; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Merck; Mitsubishi Tanabe Pharma; Mylan; Neurocrine; Noven; Otsuka; Pfizer; Recordati; Rovi; Sumitomo Dainippon; Sunovion; Supernus; Takeda; Teva
Served as a speaker or a member of a speakers bureau for: Angelini; Gedeon Richter; Janssen/J&J; Lundbeck; Mitsubishi Tanabe Pharma; Mylan; Sumitomo Dainippon; Otsuka; Recordati; Sunovion
Received grants for clinical research from: Janssen; Takeda
Owns stock, stock options, or bonds from: LB Pharma
Other: DSMB member or chair: Lundbeck; Relmada; ROVI; Teva

Diana Perkins, MD

Professor
Department of Psychiatry
Director of Early Psychosis Interventions-North Carolina Consultants
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Disclosures

Disclosure: Diana Perkins, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alkermes
Received grants for clinical research from: Boehringer Ingelheim

Editors

Lisette Arnaud-Hevi, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lisette Arnaud-Hevi, PhD, has disclosed no relevant financial relationships.

Walid Amara, MD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Biotronix; Servier. Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; LivaNova; MEDA; Medtronic, Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Physiomed; St. Jude, Servier

Christin Melton, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Christin Melton, ELS, has disclosed no relevant financial relationships.

CME Reviewer

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Psychiatry & Mental Health

CME

The Emerging Receptor Science in the Management of Schizophrenia

Authors: Christoph Correll, MD; Diana Perkins, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 6/10/2021; Reviewed and Renewed: 9/14/2022

Valid for credit through: 9/14/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to increase knowledge of how new scientific findings related to the pathophysiology of schizophrenia are resulting in new therapies for schizophrenia.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Christoph Correll, MD

Diana Perkins, MD

Editors

Lisette Arnaud-Hevi, PhD

Walid Amara, MD

Christin Melton, ELS

CME Reviewer

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Peer Reviewer

CME

The Emerging Receptor Science in the Management of Schizophrenia

Target Audience and Goal Statement

Disclosures

Faculty

Christoph Correll, MD

Diana Perkins, MD

Editors

Lisette Arnaud-Hevi, PhD

Walid Amara, MD

Christin Melton, ELS

CME Reviewer

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Emerging Receptor Science in the Management of Schizophrenia

Educational Impact Challenge